Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 5/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925185 | 1.00 | ATM (0.44) | ATMCASP3CASP7SIGMAR1NAAA | |
| SCHEMBL21804965 | 1.00 | ATM (0.44) | ATMCASP3CASP7SIGMAR1NAAA | |
| SCHEMBL6426998 | 0.88 | KMT2A (0.47) | CASP3CASP7SIGMAR1NAAAFAAH | |
| SCHEMBL191824 | 0.88 | GFER (0.44) | ATMCASP3CASP7SIGMAR1NAAA | |
| SCHEMBL191823 | 0.88 | GFER (0.44) | ATMCASP3CASP7SIGMAR1NAAA | |
| SCHEMBL1915646 | 0.88 | NAAA (0.47) | NAAAFAAHALDH1A1 | |
| SCHEMBL1915643 | 0.88 | NAAA (0.47) | NAAAFAAHALDH1A1 | |
| SCHEMBL7346791 | 0.88 | NAAA (0.47) | NAAAFAAHALDH1A1 | |
| SCHEMBL16307020 | 0.86 | KDM4E (0.44) | SIGMAR1NAAAFAAH | |
| SCHEMBL1919141 | 0.86 | KDM4E (0.44) | SIGMAR1NAAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021055668-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020061252-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-9409886-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2170863-B1 | Pyrimido cyclopentanes useful for the treatment of inflammatory or hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8618097-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2170863-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | ATM 633/4885CASP3 1950/4885CASP7 1804/4885 |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | ATM 633/4885CASP3 1950/4885CASP7 1804/4885 |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | ATM 563/4885CASP3 1789/4885CASP7 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.